Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 71Neoplasm Metastasis 11Brain Neoplasms 7Triple Negative Breast Neoplasms 5Stomach Neoplasms 3Neoplasms 3HER2-positive Breast Cancer 3Colorectal Neoplasms 3Advanced Breast Cancer 3Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Unresectable Locally Recurrent Breast Cancer 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Inflammatory Breast Neoplasms 1HER2-negative Breast Cancer 1HER2-low Hormone Receptor Positive Breast Cancer 1HER2-Positive Primary Breast Cancer 1HER2 Overexpression 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1rebastinib 1pembrolizumab 1ceralasertib 1belinostat 1X-Rays 1Paclitaxel 1Nivolumab 1Immunoglobulin G 1Fluorouracil 1DCC-2036 1Cyclophosphamide 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × trastuzumab deruxtecan × Breast × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡